Genetic mechanism for the loss of PRAME in B cell lymphomas

MRÁZ, Marek. Genetic mechanism for the loss of PRAME in B cell lymphomas. Journal of Clinical Investigation. Ann Arbor: AMER SOC CLINICAL INVESTIGATION INC, 2022, vol. 132, No 14, p. nestrankovano, 1 pp. ISSN 0021-9738. Available from: https://dx.doi.org/10.1172/JCI160983.

Basic information

• Original name: Genetic mechanism for the loss of PRAME in B cell lymphomas
• Authors: MRÁZ, Marek (203 Czech Republic, guarantor, belonging to the institution).
• Edition: Journal of Clinical Investigation, Ann Arbor, AMER SOC CLINICAL INVESTIGATION INC, 2022, 0021-9738.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 30205 Hematology
• Country of publisher: United States of America
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• Impact factor: Impact factor: 15.900
• RIV identification code: RIV/00216224:14740/22:00127432
• Organization unit: Central European Institute of Technology
• Doi: http://dx.doi.org/10.1172/JCI160983
• UT WoS: 000844140900002
• Keywords in English: CHRONIC LYMPHOCYTIC-LEUKEMIA22Q11
• Tags: 14110212, podil, rivok
• Tags: International impact, Reviewed

Abstract

To the Editor: Takata et al. (1) reported that patients with diffuse large B cell lymphoma (DLBCL) relatively frequently (13% of patients) harbor a deletion at the 22q11.22 locus that involves the PRAME gene, and that PRAME loss is associated with poor outcomes and leads to cytotoxic T cell immune escape. The authors comment that “deletions...were located close to the Igλ gene.” I would like to bring to the attention of the authors and readers that the PRAME gene and neighboring ZNF280A, ZNF280B, and GGTLC2 genes are located between variable (V) subgenes for the immunoglobulin lambda (Igλ) light chain (Figure 1). The PRAME deletion is inevitable when a B lymphocyte (normal or malignant) rearranges the Igλ locus and utilizes one of the many V subgenes located more distantly from the J-C region. It is known that approximately 30% to 40% of B lymphocytes express Igλ (~60%–70% express Igκ, since this locus for the Ig light chain is rearranged before Igλ). Therefore, it is not surprising that the loss of PRAME has been previously noted in multiple B cell malignancies, especially chronic lymphocytic leukemia (2–4). Takata et al. (1) observed that patients with PRAME deletions more often have an Igλ rearrangement, but they also report cases of DLBCL with a PRAME deletion and rearranged Igκ.